Abstract: The is invention is directed to a composition useful for assisting in supplying a warm-blooded animal with many of its nutritional needs. More specifically, this invention is directed to a composition whereby many of the vitamins, minerals, amino acids and cofactors are suspended in a matrix which when administered to a mammal provides substantial benefit.

Abstract: A composite material comprising an inorganic filler material and a oriented fibrous polymeric material characterised in that the fibrous material has areas of adjacent fibres fused together to form a network or continuous matrix while retaining oriented fibrous structure in the composite.

Abstract: A bioactive sol-gel solution includes a biocompatible polymer, a gelable inorganic base material, and at least one calcium and phosphorous molecular species. The base material can be an alkoxide, such as TEOS. The polymer acts as a viscosity modifier to the sol or gel, increases the viscosity range over which fibers can be sprayed or spun, and broadens the time period over which fibers can be sprayed or spun. A bioactive glass composite can be formed from the bioactive sol-gel solution, including a fibrous form. Fibers can serve as a scaffold for cell growth and in the repair of hard or soft tissue defects.

Abstract: A biomimetically produced bone-analogous coating, comprising organic and inorganic main constituents, is suitable for coating metallic implant materials of any desired surfaces. The coating comprises a collagen matrix mineralized with calcium phosphate.

Abstract: A composition for controlling growth of pathological organisms on a plant, said composition comprises an effective amount of one or more of metal ion(s); one or more of chelating agent(s); and phosphorous acid, and/or salt or hydrate thereof, said composition is in an agriculturally compatible carrier or vehicle.

Abstract: A biodegradable ceramic for medical use is disclosed, which comprises calcium hydrogenphosphate (CaHPO4) modified by organic molecules. The organic molecule mentioned above is hexamethylene diisocyanate (HMDI), which is grafted to the calcium hydrogenphosphate through covalent bond. The present invention also relates to a method for preparing the biodegradable ceramics. In addition, the biodegradable ceramic can be used for repair of bone defects. Therefore, the present invention further relates to a method and a device for repair of bone defects, and to a delivery system for the medicine of repair of bone defects.

Abstract: The invention provides a hydroxyapatite composition for replenishing calcium, comprising 5 to 80 wt % hydroxyapatite with particle size of 5-800 nm and pharmaceutically acceptable excipient. The composition may comprise organic acid, such as citric acid, malic acid, starch, dextrin, sugar, Vitamin D, Vitamin A, Vitamin B, Vitamin C, and Vitamin E, and trace clement(s) selected from the group consisting of Sr, F, Fe, Zn, and Mn. The composition may be in solid preparation form such as powder, tablet, including coated tablet, capsule, and infusion (medicinal granules), and liquid preparation form such as oral liquid, injection solution, and beverage; and ion introduction type transdermal-preparation, etc. Furthermore the composition can be incorporated into any other foods. The composition of the invention can be made into different type of products including general type, children type, pregnant women type, liver and kidney type and climacteric type to meet the need of different people.

Abstract: The combination of erythropoietin and calcium, with or without phosphates, is useful for treating haemochromatoses. A method for treating primary haemochromatoses in a patient involves administering to the patient a combination therapy including an erythropoietin preparation and a calcium preparation, where the erythropoietin preparation and the calcium preparation are each administered from 1 to 5 times weekly. Beneficially, this combination therapy further administers a phosphorus preparation.

Abstract: The invention describes a wet-chemical process for the preparation of alpha- and beta-tricalcium phosphate (TCP) powders. The procedure simply comprises immediate addition of di-ammonium hydrogen phosphate to an aqueous solution of calcium nitrate tetrahydrate, or vice versa. Calcination of the recovered precursor powders at 800° C. in air produces beta-TCP, whereas the calcination of the same at 1200° C., followed by rapid cooling to room temperature yields submicron-particulated alpha-TCP powders. These powders can be the raw materials for bioceramics, such as artificial bones, artificial joints, artificial tooth roots, and calcium phosphate-based self-setting, self-hardening cements.

Abstract: A solid surface material with a filler and an antibacterial agent in a thermoset or thermoplastic matrix, which has antibacterial effectiveness that can be restored when lost or diminished with time and use.

Abstract: NGF microencapsulation compositions having controlled release characteristics, preferably with increased stability, for the NGF component, particularly human recombinant NGF (“rhNGF”) are provided that yield enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function. Methods for making and using such compositions are also provided.

Abstract: The present invention provides a formulation for the delivery of bioactive constituents to biological surfaces, wherein said formulation comprises a suspensions or solution of at least one isolated and purified casein protein or salt thereof, in water, together with at least one bioactive constituent.

Abstract: The present invention relates to a novel pharmaceutical composition and process for preparing swallowable methylcellulose tablets that disintegrate rapidly and meet USP standards in 0.1 N hydrochloric acid as well as water.

Abstract: A biological material for treating periodontal diseases and all related disorders, the biomaterial comprising biocompatible bioaragonite, added calcium carbonate and optionally a binding agent. The bioaragonite is mother-of-pearl in micronised form. It is obtained by inhibiting the most immunogenic part of the bioaragonite organic substance so as to maintain bioactive only the organic part associated with the mineral capable of having a positive effect.

Abstract: The present invention provides a method and composition for dietary vitamin supplementation utilizing a form and dosage of vitamins and minerals for enhanced calcium absorption. The method includes the steps of providing a pharmaceutically acceptable composition including calcium citrate, and supplementing the daily dietary regimen of a subject with calcium citrate within the range of approximately 100 mg calcium to approximately 2000 mg calcium, and preferably 1000 mg calcium. The chewable form of the supplement provided herein facilitates absorption of calcium in the teeth and bones of a subject, for enhanced physiological and psychological benefits. The supplement is especially beneficial for subjects experiencing osteoporosis, arthritis, demineralization of teeth and bones, bodily pain and lack of energy, as well as for the prevention of these ailments.

Abstract: A porous &bgr;-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 &mgr;m, preferably 50-125 &mgr;m. The porous &bgr;-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous &bgr;-TCP, and a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous &bgr;-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous &bgr;-TCP material and inducing bone formation are also provided.

Abstract: The invention relates to a regenerative adjuvant to be used in skin and bone defects of living beings and to a method that can be carried out in any doctor's practice without the need for a specialized laboratory. The invention further relates to a kit used with this regenerative adjuvant that can be easily handled. The inventive regenerative adjuvant for skin and bone defects comprises thrombocyte-rich plasma (platelet-rich plasma) and calcium phosphates.

Abstract: The invention relates to a regenerative adjuvant to be used in skin and bone defects of living beings and to a method that can be carried out in any doctor's practice without the need for a specialized laboratory. The invention further relates to a kit used with this regenerative adjuvant that can be easily handled. The inventive regenerative adjuvant for skin and bone defects comprises thrombocyte-rich plasma (platelet-rich plasma) and calcium phosphates.

Abstract: The present invention provides comestibles and related aspects for use in maintaining canine urinary tract health. In particular the comestibles and related aspects are useful in preventing the initial occurrence of canine calcium oxalate urolithiasis. The present invention also provides a comestible, which when fed to a small breed canine animal results in a urine specific gravity of 1.025 or below, for use in preventing the initial occurrence of calcium oxalate urolithiasis in the canine animal and related aspects. The comestible includes the following ingredients in the ranges indicated, for use in preventing the initial occurrence of calcium oxalate urolithiasis in a canine animal and related aspects: 1 Nutrient g/400 kcal Calcium 0.65-1.3 Phosphorus 0.5-1.2 Magnesium from 0.04 Potassium from 0.5 Sodium 0.6-1.

Abstract: The present invention relates to a tabletted water sanitizer having improved stability and controlled solubility is disclosed and method of making the same. The tabletted sanitizer is preferably comprised of calcium hypochlorite and a dissolving rate controlling amount of poly(maleic acid) salt. Preferably, the calcium hypochlorite has at least 60% available chlorine, and most preferably at least 70% available chlorine. The tablet (or briquette) has between about 0.001% and 20% of the poly(maleic acid) salt, preferably sodium poly(maleic acid), calcium poly(maleic acid) or mixtures thereof. Tablets may be formed using any tabletting or briquetting technique commonly known in the art.

Abstract: This invention relates to bioabsorbable materials and implants used to prevent and treat infection and promote bone growth. More specifically, this invention relates to synthetic bioabsorbable drug delivery materials and implants comprising: (a) a synthetic bioabsorbable polymeric matrix; (b) an antibiotic phase dispersed into said polymeric matrix; and (c) antibacterial, bioabsorbable, bioactive glass, dispersed into said polymeric matrix for the promotion of bone growth.

Abstract: A novel bone-strengthening agent, a bone-strengthening food composition and a bone-strengthening feed composition which aim at preventing a decrease in bone density in association with the onset or progress of osteoporosis. It is found out that not merely added-up effects but synergistic effects can be achieved by the combined use of CPP, which is known as promoting the absorption of calcium essentially required for the soundness of bone and thus exerting an effect of strengthening bone, with genistein which directly acts on the bone tissue, inhibits bone resorption, and promotes osteogenesis and thus exerts an effect of strengthening bone.

Abstract: A solid powder product with a Ca/P ratio of between 1.40 and 1.90 is prepared from tricalcium phosphate and tetracalcium phosphate. An aqueous solution containing calcium ions and phosphate ions with a Ca/P ratio higher than 0.20 and lower than 0.50 is prepared. The aqueous solution and the solid powder product and optionally water are mixed to obtain a mixture with a liquid/solid weight ratio of between 0.30 and 0.65 and a resulting paste with a Ca/P ratio of between 1.50 and 1.67.

Abstract: A method for controlling the formation of a hydroxyapatite bone filler from dry calcium phosphate precursors in an aqueous solution uses coated sodium phosphate powder. The sodium phosphate powder is coated with a water soluble cellulose. Until the cellulose dissolves in the aqueous solution setting of the calcium phosphate cements proceeds slowly but when the exposed sodium phosphate particles start to solubilize in the aqueous solution the setting rate increases.

Abstract: Conditioning of the surface of silica-based glass or ceramic by differential immersion in a serum protein-containing solution, and the resultant microporous Ca-P surface layer having serum-protein like organic molecules, as defined herein intermingled throughout, is described.

Abstract: A multinutrient nutritional supplement is provided that is designed to be most effective in optimizing health, increasing the immunity and decreasing the instances and severity of infection particularly among children.

Abstract: Synergistic fungicidal composition comprising a compound analogous to strobilurin of formula (I): in which: A is the nitrogen atom or the —CH group, B is the —OCH2— or —CH2O— or CH(CH3)—O—N═CH— or —CH═N—O—CH(CH3)— group or the group R1 is an alkyl group containing 1 to 4 carbon atoms, R2 is —OCH3 or —NHCH3, X is a halogen atom, the cyano group or an alkyl or haloalkyl group containing 1 to 4 carbon atoms, n is equal to 1 or 2, with, when n is equal to 2, the possibility of having different X groups, and at least one fungicidal compound B, and a process for the curative or preventive control of phytopathogenic fungi using the composition.

Abstract: A multinutrient nutritional supplement is provided that is designed to be most effective in optimizing health, increasing the immunity and decreasing the instances and severity of infection particularly among adolescents.

Abstract: A method for controlling the formation of a hydroxyapatite bone filler from dry calcium phosphate precursors in an aqueous solution uses coated sodium phosphate powder. The sodium phosphate powder is coated with a water soluble cellulose. Until the cellulose dissolves in the aqueous solution setting of the calcium phosphate cements proceeds slowly but when the exposed sodium phosphate particles start to solubilize in the aqueous solution the setting rate increases.

Abstract: Various compositions containing transfer factor in combination with nutraceuticals are provided including transfer factor in combination with zinc and essential fatty acids and transfer factor in combination with lactic acid generating bacteria. Also provided are methods for treating animal diseases and syndromes using these compositions.

Abstract: Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a calcium glutarate compound. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to increase available calcium and contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.

Abstract: This invention relates to a buffered phosphorus containing solution comprising at least one phosphorus compound selected from the group consisting of phosphorous acid, hypophosphorous acid, polyphosphorous acid polyhypophosphorous acid, and salts thereof. The solution also contains a buffer including an organic base in the form of a nitrogen containing compound and its conjugate acid. The solution may be used as a fertilizer or as a fungicide. The invention also relates to a method of preparing such a solution.

Abstract: The present invention provides delivery vehicles comprising a synthetic, poorly crystalline apatite (PCA) calcium phosphate and a biologically active agent. The PCA calcium phosphate offers many advantages over known delivery materials and is particularly useful for delivery of agents to bone sites, the central nervous system, intramuscular sites, subcutaneous sites, interperitoneal sites, and occular sites. The invention also provides methods of preparing delivery vehicles, of altering delivery vehicle characteristics, and of delivering biologically active agents to a site. The invention is useful for both medical and veterinary applications.

Abstract: Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.

Abstract: An artificial bone promotive of osteoanagenesis comprising a calcium phosphate cement and a linear polyphosphate, wherein the calcium phosphate cement comprises &bgr;-tricalcium phosphate, monocalcium phosphate, calcium sulfate hemihydrate and other additives. The artificial bone is non-toxic to the body chemically stable, and has an excellent biodegradability. The artificial bone may be applied as substitutes for bone cements, allografts and autografts.

Abstract: A porous &bgr;-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 &mgr;m, preferably 50-125 &mgr;m. The porous &bgr;-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. The invention provides a kit and an implant device comprising the porous &bgr;-TCP, and one or more additional components including a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous &bgr;-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous &bgr;-TCP material and inducing bone formation are also provided.

Abstract: The present invention provides a novel process for producing a calcium phosphate cement or filler which hardens in a temperature dependent fashion in association with an endothermic reaction. In the reaction a limited amount of water is mixed with dry calcium phosphate precursors to produce a hydrated precursor paste. Hardening of the paste occurs rapidly at body temperature and is accompanied by the conversion of one or more of the reactants to poorly crystalline apatitic calcium phosphate. The hardened cements, fillers, growth matrices, orthopedic and delivery devices of the invention are rapidly resorbable and stimulate hard tissue growth and healing. A composite material is provided including a strongly bioresorbable, poorly crystalline apatitic calcium phosphate composite and a supplementary material. The supplementary material is in intimate contact with the hydroxyapatite material in an amount effective to impart a selected characteristic to the composite.

Abstract: Shaped, preferably porous, inorganic bodies are provided which are prepared from a reactive blend. In accordance with one preferred embodiment, the solution is absorbed into a porous sacrificial substrate such as a cellulose sponge. The solution-saturated substrate is heated and an oxidation-reduction reaction occurs thereby forming an inorganic solid. A shaped, inorganic body is formed in situ. Optional, but preferred additional thermal treatment of the shaped, inorganic body removes the organic substrate, leaving an inorganic body that faithfully mimics the porosity, shape, and other physical characteristics of the organic substrate. Inorganic substrates may also be used to good effect. Large varieties of shaped bodies can be prepared in accordance with other embodiments of the invention and such shapes find wide use in surgery, laboratory and industrial processes and otherwise. The invention also provides chemically and morphologically uniform powders, including those having uniformly small sizes.

Abstract: A solid powder product with a Ca/P ratio of between 1.40 and 1.90 is prepared from tricalcium phosphate and tetracalcium phosphate. An aqueous solution containing calcium ions and phosphate ions with a Ca/P ratio higher than 0.20 and lower than 0.50 is prepared. The aqueous solution and the solid powder product and optionally water are mixed to obtain a mixture with a liquid/solid weight ratio of between 0.30 and 0.65 and a resulting paste with a Ca/P ratio of between 1.50 and 1.67.

Abstract: A dietary supplement composition contains phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus, and may, optionally, further contain Vitamin D, Vitamin B12, folate and Vitamin B6, provides components that have been linked to bone health.

Abstract: The invention concerns a method for preparing a calcium phosphate pasty material for injection which after, setting, is designed to form an apatite material. Said method consists in: producing from water and calcium phosphates pasty mixture capable of developing, hardening and forming a hydroxyapatite. Said method is characterized in that it consists in adding to the calcic phosphates or to the pasty mixture before it is injected a methicone having relative to the mixture more than 0.30 wt. % and less than 10 wt. %. The resulting material can be injected, that is it can be transported in pasty form into a conduit under moderate pressure levels. Said material sets on the site of implantation and hardens to form an apatite biomaterial in a manner similar to known methicone-free calcium phosphate mixtures.

Abstract: Nutritional mineral supplements comprising calcium citrate malate and vitamin D are disclosed. Estrogen can also be used with these supplements. These supplements, which provide at least 25% RDA of calcium and vitamin D are used in addition to the normal diet. These supplements are useful for increasing bone growth and for treating age-related bone loss in humans and animals.

Abstract: The present invention relates to an orally administered composition to relieve stress comprising from about 100 mg to about 2000 mg of at least one antacid, about 50 mg to about 500 mg of at least one anxiety reducing compound wherein the amount of anxiety reducing compound is based on a concentrated extract containing not less than 0.5% of the essential oil of the respective anxiety reducing compound, and about 20 mg to about 600 mg of at least one mental alertness inducing compound wherein the amount of the mental alertness inducing compound is based on a concentrated extract of the respective mental alertness inducing compound. The anti-stress compositions simultaneously provide the user with a considerable sense of well-being by providing relief from excess gastrointestinal acidity, reducing anxiety, and increasing mental alertness or thinking ability. The overall sense in the user is that stress is reduced emotionally as well as physically as a result of the effects of the present invention.

Abstract: The present invention is directed to a synthetic biomaterial compound based on stabilized calcium phosphates and more particularly to the molecular, structural and physical characterization of this compound. The compound comprises calcium, oxygen and phosphorous, wherein at least one of the elements is substituted with an element having an ionic radius of approximately 0.1 to 1.1 Å. The knowledge of the specific molecular and chemical properties of the compound allows for the development of several uses of the compound in various bone-related clinical conditions.

Abstract: The therapeutic combination comprises as its associated active ingredients calcium in elemental form and at least one vitamin D. It also contains at least one dry and moist binder combined in synergistic quantity with at least one diluant, at least one binder, and at least one lubricant, at least one of said diluant and said binder being a sweetening agent. Advantageously, the ratio of calcium in elemental form to vitamin D, expressed in mg of elemental Ca per IU of vitamin D lies in the range 1 to 1.5, and preferably in the range 1.2 to 1.3.

Abstract: This invention relates, generally, to nutritional supplements which contain bioactive glass. These supplements are useful in both veterinary and human contexts. The compositions of the subject invention can be used to achieve a number of advantageous results including: enhancing the growth rates of young animals, osteogenic stimulation, strengthening the skeletal structure, and treating osteoporosis.

Abstract: Disclosed are compositions of a novel astringent and keratolytic topical pharmaceutical base into which drugs can be incorporated such as for example an anti-pruritic drug and/or an anti-inflammatory drug.

Abstract: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

Abstract: A calcium formate composition for oral administration to an individual for the purpose of inhibiting gastrointestinal absorption of phosphorus is disclosed. A method of inhibiting gastrointestinal absorption of phosphorus, comprising administering orally the composition, preferably close in time to food and beverage consumption is also disclosed.

Abstract: The invention relates to an injectable curable bone cement paste based on bioresorbable hydroxyapatite-like compounds comprising calcium phosphate, which contains a cationic antibiotic in the form of a salt, preferably of its sulfate, the curable biodegradable bone cement releasing the antibiotic in biologically active concentrations with depot-like action over a long period of time. The bone cements according to the invention are suitable for the treatment of infectious inflammations of the bone and of the bone marrow, in particular as a result of bone defects and bone fractures.